Pharmaceutical giant Pfizer close to reach $9b deal with Nestle

Pharmaceutical giant Pfizer close to reach $9b deal with Nestle

PanARMENIAN.Net - U.S. pharmaceutical giant Pfizer is close to reaching a $9 billion deal to sell its infant nutrition business to Nestle, AFP reports citing the Wall Street Journal.

The Journal said Nestle, the Swiss food giant, had apparently beaten out Groupe Danone and Mead Johnson Nutrition, which had considered a joint bid for the business, and that the final deal could be announced next week.

A Pfizer spokeswoman contacted by AFP refused to comment on the report, saying "no decisions have been made at this point" on the sale of the infant nutrition business or an animal health business also set to be auctioned off.

"The animal health and nutrition businesses are highly valued assets, and our decision about strategic options will be driven by value creation and delivering the best after-tax value for our shareholders," she said.

Pfizer has moved to unload peripheral entities in recent months in order to focus on its core medicine business.

In November its patent on the best-selling drug of all time, the cholesterol-lowering medication Lipitor, expired, opening the path to generic competitors for America's most popular medication.

 Top stories
Aleksei Miller was also scheduled to meet with government officials in Germany, which is a major customer of Gazprom’s supplies.
Access to finance is a major impediment to the growth of micro, small and medium enterprises, especially in the rural areas.
Armenia saw remarkable economic growth and poverty reduction in the period preceding the global financial crisis of 2008–2009.
Priority needs will be identified through assessments of economic development potential and prioritization by the communities.
Partner news